Research · Sep 3, 2026
[BAX] Baxter International Thesis 2026: Post-Vantive Reset Tests Hospital Capex Recovery
Baxter International FY2025 revenue ~$10-10.5B (+0-2% post-Vantive Kidney Care divestiture) with adj. EPS ~$2.00-2.20 reflecting post-Vantive Kidney Care divestiture (November 2024 sold to Carlyle Group ~$3.8B; substantial revenue base reduction from ~$15B to $10-10.5B post-divestiture) + selected hospital capex pressure + selected operational reset under interim CEO Brent Shafer + selected dividend reduction. Global medical device + medical products company; founded 1931 by Donald Baxter as small intravenous solution provider. 3 segments post-Vantive: Medical Products & Therapies ~50% ($5B — medication delivery IV solutions + pumps + nutrition) + Healthcare Systems & Technologies ~30% ($3B — Hill-Rom medical beds + patient monitoring + hospital workflow) + Pharmaceuticals ~20% ($2B — compounding + sterile pharmaceuticals). CEO Brent Shafer interim since 2024 (succeeded Joe Almeida CEO 2016-early 2024 who departed amid Hillrom acquisition integration challenges + selected board pressure; Shafer former Hill-Rom CEO + ~30+ year hospital equipment industry executive). Major strategic events: Hillrom $10B acquisition December 2021 (selected integration challenges + leverage burden); Vantive Kidney Care divested to Carlyle Group November 2024 (~$3.8B; peritoneal + hemodialysis dialysis products ~$4.5B revenue); dividend reduced $1.16 → $0.68 in 2024 (ended dividend aristocrat status — selected painful cut to refinance debt). Capital return: dividend $0.68-0.72/share + minimal buybacks; net debt $11-12B (declining from $17B FY2022); Baa2/BBB+ investment grade. FY2026 thesis: post-Vantive reset + permanent CEO + hospital capex + leverage management. Risks: hospital capex cycle, leverage, M&A integration.